Sila-Analogues of vitamin D with low/neglibible toxic calcemic side effects

Summary of the technology

The present application describes the synthesis and biological applications of new vitamin D analogues based on the C-to-Si exchange in the side chain, along with several groups at the Si atom, such as alkyl, hydrogen, or hydroxyl. It is focused on i) 1,25D derivatives, ii) procedures for obtaining them, iii) their intermediates, and iv) their pharmacological applications. The new analogues can be used to develop new drugs with antitumor action or with action on other diseases by acting on the VDR receptor (psoriasis, Alzheimer's, osteoporosis, diabetes, hypertension, low immunity, rickets) with low or negligible toxic calcemic side effects.

University of Porto

Details of the Technology Offer

Background:

The main metabolite of vitamin D3, 25-hydroxyvitamin D3, is hydroxylated at c-1 in the kidneys to produce the physiologically active form 1,25D (calcitriol). This natural hormone has a wide range of functions, including mineral homeostasis (calcium and phosphorous metabolism) and various antiproliferative, pro-differentiative, and immunomodulatory properties. The clinical dose of 1,25D is responsible for calcemic side effects.

Benefits:

The new analogues have a similar cell differentiation in comparison with 1,25D with diminished or non-calcemic side effects. One of the analogues is responsible for significantly increasing the weight of the animals which may suggest an increase in bone density. It was observed a slower proliferation rate of tumoral cells and a great ability to activate target genes of 1,25D for all analogues and 1,25D in comparison with the control.

Potential comercial use/applications:

Drugs - Prophylactic and/or therapeutic agent for vitamin D receptor-related diseases; Supplements - Prophylactic agent for vitamin D receptor-related diseases

  • Process number:Europe - Patent Application No. 22723183.4; Portugal - Patent No. PT117825; Spain - Patent No. ES2946255
  • Patent status:Europe pending | Portugal granted | Spain granted
  • Cooperation options:Licensing agreement;Research partnership.
  • Technology Readiness Level:Technology Readiness Level 3: experimental proof of concept.

Related Keywords

  • Cytology, Cancerology, Oncology
  • cancer
  • psoriasis
  • osteoporosis
  • anti-tumoral
  • sila-analogues
  • vitamin d receptor
  • 25-dihydroxyvitamin d3 (calcitriol) analogues
  • antiproliferative
  • cell differentiation
  • affinity for vdr

About University of Porto

U.Porto Inovação was established in 2004 to support the University’s innovation value chain by facilitating the transfer of knowledge and strengthening the relationship between the University and businesses. With over 20 years of experience, U.Porto Innovation focuses its activities on research at the University, entrepreneurship within the academic community and U.Porto’s growing connections with industry.

University of Porto

Never miss an update from University of Porto

Create your free account to connect with University of Porto and thousands of other innovative organizations and professionals worldwide

University of Porto

Send a request for information
to University of Porto

About Technology Offers

Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.

Help

Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support